XFOR
HEALTHCAREX4 Pharmaceuticals Inc
$4.38+0.18 (+4.29%)PRE
Live · NASDAQ · May 8, Close
AI Insight
What's Moving XFOR Today?
No stock-specific AI insight has been generated for XFOR yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.35$4.83
$4.38
Fundamentals
Market Cap$413M
P/E Ratio—
EPS$-2.07
Dividend Yield—
Dividend / Share—
ROE-0.8%
Profit Margin-2.3%
Debt / Equity—
Trading
Volume652K
Avg Volume (10D)—
Shares Outstanding94.3M
XFOR News
20 articles- X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue EstimatesYahoo Finance·May 6, 2026
- X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate UpdateYahoo Finance·May 6, 2026
- Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 5, 2026
- X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European UnionYahoo Finance·Apr 29, 2026
- One X4 Pharmaceuticals Insider Raised Their Stake In The Previous YearYahoo Finance·Apr 9, 2026
- X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Apr 1, 2026
- X4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue EstimatesYahoo Finance·Mar 17, 2026
- X4 Pharmaceuticals: Q4 Earnings SnapshotYahoo Finance·Mar 17, 2026
- X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Mar 17, 2026
- ProQR (PRQR) Reports Q4 Loss, Lags Revenue EstimatesYahoo Finance·Mar 12, 2026
- X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention247 Wall St·Mar 9, 2026
- X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare ConferenceYahoo Finance·Mar 4, 2026
- X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM SyndromeYahoo Finance·Feb 27, 2026
- Vericel Corporation (VCEL) Matches Q4 Earnings EstimatesYahoo Finance·Feb 26, 2026
- X4 Pharmaceuticals Details Mavorixafor Phase 3 Push, Cost Cuts and Chronic Neutropenia Market PlanMarketbeat·Feb 16, 2026
- X4 Pharmaceuticals to Participate in Guggenheim’s Emerging Outlook: Biotech Summit 2026Yahoo Finance·Feb 3, 2026
- X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) largest shareholders are individual investors with 52% ownership, institutions own 31%Yahoo Finance·Jan 18, 2026
- All You Need to Know About X4 Pharmaceuticals (XFOR) Rating Upgrade to BuyYahoo Finance·Jan 12, 2026
- Should You Buy X4 Pharmaceuticals (XFOR) After Golden Cross?Yahoo Finance·Dec 24, 2025
- Tracking the Evolving Narrative for X4 Pharmaceuticals After Financing and Restructuring MovesYahoo Finance·Dec 8, 2025
All 20 articles loaded
Price Data
Open$4.21
Previous Close$4.20
Day High$4.50
Day Low$4.13
52 Week High$4.83
52 Week Low$1.35
52-Week Range
$1.35$4.83
$4.38
Fundamentals
Market Cap$413M
P/E Ratio—
EPS$-2.07
Dividend Yield—
Dividend / Share—
ROE-0.8%
Profit Margin-2.3%
Debt / Equity—
Trading
Volume652K
Avg Volume (10D)—
Shares Outstanding94.3M
About X4 Pharmaceuticals Inc
X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of new therapies for the treatment of back diseases. The company is headquartered in Boston, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—